お気に入りに追加
製品詳細
Synonyms
FCGR3
Source
Biotinylated Cynomolgus CD16, His,Avitag (FC6-C82E0) is expressed from human 293 cells (HEK293). It contains AA Gly 17 - Gln 208 (Accession # Q8SPW2-1).
Predicted N-terminus: Gly 17
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 25.7 kDa. The protein migrates as 36-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Labeling
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Protein Ratio
Passed as determined by the HABA assay / binding ELISA.
Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
お客様はこちらも閲覧
データ表示
SDS-PAGE
Biotinylated Cynomolgus CD16, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
SEC-MALS
The purity of Biotinylated Cynomolgus CD16, His,Avitag (Cat. No. FC6-C82E0) is more than 95% and the molecular weight of this protein is around 35-50 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Rituximab at 5 μg/mL (100 μL/well) can bind Biotinylated Cynomolgus CD16, His,Avitag (Cat. No. FC6-C82E0) with a linear range of 0.039-1.25 μg/mL (QC tested).
Protocol
Bioactivity-SPR
Captured Biotinylated Cynomolgus CD16, His,Avitag (Cat. No. FC6-C82E0) on Biotin CAP - Series S sensor Chip can bind MabThera® (Rituximab) with an affinity constant of 0.63 μM as determined in a SPR assay (Biacore T200) (Routinely tested).
Protocol
Bioactivity-BLI
Loaded Biotinylated Cynomolgus CD16, His,Avitag (Cat. No. FC6-C82E0) on SA Biosensor, can bind Rituximab with an affinity constant of 0.401 μM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).
Protocol
ユーザーレビュー コメントを投稿
バックグランド
CD16a antigen is also known as Low affinity immunoglobulin gamma Fc region receptor III-A, Fc-gamma RIII-alpha. CD16b is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas CD16a is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placentaltrophoblasts.CD16a is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibodydependent cytotoxicity and clearance of immune complexes. Aberrant expression or mutations of CD16a is implicated in susceptibility to recurrent viral infections, systemic lupus erythematosus, and alloimmune neonatal neutropenia.
最新の進展
医薬品開発の進捗- 英語名：
Low affinity immunoglobulin gamma Fc region receptor III-A
- カテゴリ：
- 市販の医薬品数：
0 詳細
- 治験医薬品数：
14 詳細
- 最新の開発ステージ：
Phase 2 Clinical
お問い合わせ
メールアドレス
order.jp@acrobiosystems.com
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
医薬品候補ライセンス
